

Prescribing trends and unmet medical need in the treatment of mild and moderate atopic dermatitis among dermatologists and primary care physicians in the United States

Pierette Kiewiet de Jonge, Leslie Wardwell-Scott, Sudhakar Mandapati, Lauren Hess, Maggie Ercolani, Julia Comer, Mark D. Plinio

Evelo Biosciences, Cambridge MA (Disclosure: all listed authors are employees of Evelo Biosciences or Strategic Research Insights)



Introduction

Atopic dermatitis (AD) is a chronic systemic inflammatory disease affecting an estimated 200 million people worldwide¹⁻³, including approximately ten million diagnosed patients in the United States (U.S.)⁴. The vast majority of patients suffer from mild and moderate disease. These patients are primarily treated by dermatologists and primary care physicians (PCPs).


This study aimed to evaluate the current prescribing trends among dermatologists and PCPs in the treatment of AD in the U.S. and unmet medical needs that they see for their patients.

Methods

For this research, a structured, online quantitative survey was conducted among 95 dermatologists and 37 PCPs. The fieldwork took place in January and February 2022. All product share results provided by physicians were weighted by reported patient volume, meaning responses from a physician who treated more AD patients carried more weight than responses from a physician who treated fewer AD patients in the aggregated results. Physicians self-assessed the severity of patients based on clinical practice.

Dermatologists and PCPs indicate that about three-quarters of their AD patients are mild-to-moderate

Atopic Dermatitis Patients Personally Managed Across Severities (Percent of Patients)




Question: In the past 3 months, how many adult patients have you personally managed with the following dermatological conditions? Question: Thinking of the adult Atopic Dermatitis patients you have personally managed in the past 3 months, how many would you describe as mild, moderate, and severe?

Figure 1. Dermatologists reported seeing on average three times more AD patients than PCPs in the three months prior to the survey. The physicians reported that the majority (75%) of their patients had mild or moderate disease.

Physicians acknowledge the unmet need for therapies that are effective, safe, affordable, and durable in the treatment of mild and moderate AD patients

Unaided Responses - Unmet Needs in Treating Mild to Moderate AD Patients (Percent of Physicians)




"It would be nice to have an oral with low risk of side effects" - Dermatologist

"The biggest unmet need is the long-term efficacy of the treatments. Efficacy seems to drop as treatment goes on, requiring combination therapies." - PCP

Sorted in the descending order of 'Total' results; Responses ≥ 3% at 'Total' level are shown for clarity. Question: What are your greatest unmet needs in treating your mild to moderate AD patients?

Figure 2. When answering the open-ended question, physicians mention efficacy, safety, affordability, and durability as their top four greatest unmet needs in treating mild to moderate AD.

Physicians report dissatisfaction with currently available oral options




Question: Please rate the following statements related to AD treatment on a 1 to 7 scale, where 1 = "Strongly Disagree" and 7 = "Strongly Agree".

Figure 3. Physicians, especially dermatologists, expressed dissatisfaction with currently available oral options for mild and moderate AD patients. Moreover, physicians report that safety and tolerability drive treatment decision for mild and moderate AD patients.

Physicians report a predominant reliance on topical therapy and lower usage of treatments that address systemic inflammation

Current Usage of Atopic Dermatitis Treatments Across Severities (Patient Share)



* Calibrated. Question: Please think of the Atopic Dermatitis patients whom you have managed or treated in the past 3 months. For what percent of these patients did you prescribe the following treatments?

Figure 4. Physicians indicated that around 85% of mild and 65% of moderate (total percentage of prescriptions minus the percentage of prescriptions for oral and biologic treatment) AD patients receive treatments that do not address the systemic inflammation underlying their disease. The majority of patients were on topical treatments across disease severities.

Conclusion

Significant unmet medical need exists for new treatment options, especially oral therapies, for mild and moderate AD patients. Physicians most frequently expressed the need for effective, safe/well-tolerated, affordable, and durable treatments. In the U.S., topical therapy remains the mainstay treatment among dermatologists and PCPs. Approximately 85% of mild and 65% of moderate AD patients receive treatments that do not address the systemic inflammation underlying atopic disease.